IBD Exposure to anti-TNF agents in utero: controlling health risks

C.J. van der Woude, Shannon Kanis

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.
Original languageUndefined/Unknown
Pages (from-to)387-+
JournalNature reviews - gastroenterology & hepatology
Issue number7
Publication statusPublished - 2016

Research programs

  • EMC MM-04-20-01

Cite this